Press Releases

Updates arrive automatically.

• McGraw Hill Integrates Trusted K-12 Curriculum into Anthropic’s Claude for Teachers

  

  PR07:19:00·8m·Consumer Discretionary

  McGraw Hill Integrates Trusted K-12 Curriculum into Anthropic’s Claude for Teachers

  New agentic AI integration will give educators using Claude for Teachers the ability to access the McGraw Hill curriculum they use in the classroom to create personalized instructional materials for their students Key Highlights: Connecting to trusted curriculum through Claude for Teachers: McGraw Hill is working with Anthropic to become one of the first major K-12 core curriculum providers to make its proprietary content available to school district customers through Claude for Teachers. Helping teachers personalize high-quality instructional materials for their classroom: Educators will be able to securely access trusted McGraw Hill curriculum through Claude for Teachers using a M

  $MH
• McGraw Hill, Inc. Reports Fiscal Second Quarter 2027 Results

  

  PR07:18:00·9m·Consumer Discretionary

  McGraw Hill, Inc. Reports Fiscal Second Quarter 2027 Results

  Advances Agentic AI in Education while Driving Digital Revenue Growth Exceeded Revenue Expectations with Momentum Building for FY 2028 Growth Acceleration McGraw Hill, Inc. (NYSE:MH) ("McGraw Hill" or the "Company"), a leading global provider of education solutions for preK-12, higher education and professional learning, today announced financial results for the fiscal second quarter 2027 ended September 30, 2026. "McGraw Hill's first half fiscal year 2027 performance underscores our continued higher education market share gains, scale and deep position of trust serving over 100 million active curriculum licenses across the global education ecosystem," said Philip Moyer, President, Ch

  $MH
• Edible Garden Secures Major Private-Label Ready-to-Drink Beverage Award from One of the World’s Largest Grocery Retail Organizations

  

  PR07:17:00·10m·Consumer StaplesLow floatPenny stock

  Edible Garden Secures Major Private-Label Ready-to-Drink Beverage Award from One of the World’s Largest Grocery Retail Organizations

  Commercial Award Validates the Company’s Prairie Hills Manufacturing Platform and Advances Its Transformation into a Diversified Food, Beverage, and Nutrition Business Award Supports Development of Webster City, Iowa-Based Manufacturing Facility Designed for Annual Production Capacity Exceeding 100

  $EDBL
• Verisk Reports Third Quarter 2026 Financial Results

  

  PR07:15:00·12m·Technology

  Verisk Reports Third Quarter 2026 Financial Results

  Revenue was $809 million, up 5.3%, and up 7.4% on an organic constant currency (OCC) basis, a non-GAAP measure. Net income was $219 million, down 2.8%. Adjusted EBITDA, a non-GAAP measure, was $459 million, up 7.0%, and up 7.5% on an OCC basis. Diluted GAAP earnings per share (EPS) was $1.70, up 5.6%. Diluted adjusted EPS, a non-GAAP measure, was $1.96, up 14.0%. Net cash provided by operating activities was $267 million, down 33.8% and free cash flow, a non-GAAP measure, was $200 million, down 40.5%. The decrease was primarily due to collection timing, higher interest payments, and a prior-year tax refund that did not recur. Paid a cash dividend of 50 cents per share on September 30, 2026. Execute

  $VRSK
• Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals

  

  PR07:15:00·12m·Health Care

  Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals

  Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today welcomed the Centers for Medicare & Medicaid Services' (CMS) Calendar Year 2027 Hospital Outpatient Prospective Payment System (OPPS) final rule, which maintains separate payment for qualifying diagnostic radiopharmaceuticals. CMS also confirmed PYLARIFY TruVu (piflufolastat F 18) injection will receive Transitional Pass-Through (TPT) payment status through September 30, 2029, reflecting the full three-year TPT period

  $LNTH
• Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

  

  PR07:10:00·17m·Health CarePenny stock

  Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

  Patients on Vafseo® (vadadustat) increased to approximately 11,500 at the end of Q3 2026 representing an increase of approximately 140% from the end of Q3 2025 Q3 2026 Vafseo® (vadadustat) net product revenues of $14.8 million, impacted by customer inventory reduction and market dynamics as Vafseo's TDAPA expiration approaches Positive VOICE data demonstrating statistically significant evidence of improved safety outcomes for patients treated with vadadustat versus an ESA presented by U.S. Renal Care at ASN Kidney Week Reported Positive VOCAL topline data showing vadadustat met primary endpoint of non-inferiority to ESA in maintaining hemoglobin First patient dosed in Phase 2 open-lab

  $AKBA
• Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

  

  PR07:10:00·17m·Health CareLow floatHigh short interest

  Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

  Precision BioSciences, Inc. (NASDAQ:DTIL) ("Precision"), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the pricing of an underwritten offering of 10,235,077 shares of its common stock at a price of $7.75 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 5,893,964 shares of its common stock at a price of $7.749995 per pre-funded warrant, which represents the per share offering price for the shares of common stock less the $0.000005 per share exercise price for each pre-funded warrant. The gross proceeds to Precision f

  $DTIL
• Tripadvisor, Inc. Earnings Press Release Available on Company's Investor Relations Site

  

  PR07:07:00·20m·TechnologyHigh short interest

  Tripadvisor, Inc. Earnings Press Release Available on Company's Investor Relations Site

  Tripadvisor, Inc. (NASDAQ:TRIP) issued its third quarter 2026 earnings press release which is available now at ir.tripadvisor.com. This release is also available on the SEC website at www.sec.gov. As announced previously, the company will host a conference call this morning, Thursday, November 5, 2026, at 8:30 a.m. ET to discuss the results. The live webcast and replay will be available to the public at ir.tripadvisor.com/events-and-presentations. Replays of the webcast will be accessible for at least three months following the conference call. About Tripadvisor, Inc. The Tripadvisor Group connects people to experiences worth sharing, and aims to

  $TRIP
• Lincoln International Reports Third Quarter 2026 Financial Results

  

  PR07:05:00·22m·Finance

  Lincoln International Reports Third Quarter 2026 Financial Results

  Record third quarter and year-to-date revenues of $293.7 million and $677.1 million, representing increases of 57% and 45% year-over-year, respectivelyStrong performance across both Investment Banking Advisory and Valuations and Opinions with third quarter revenues increasing 70% and 18%, year-over-year, respectivelyThird quarter net income attributable to Lincoln International, Inc. of $9.9 million and adjusted net income of $50.2 millionDeclared dividend of $0.07 per share for fourth quarter 2026

  $LCLN
• REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights

  

  PR07:05:00·22m·Health CareHigh short interest

  REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights

  RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q1 2027, with potential accelerated approval in 2H 2027Topline data from pivotal subretinal wet AMD studies, ATMOSPHERE® and ASCENT®, expected in Q4 2026Phase IIb/III NAAVIGATE trial for diabetic retinopathy ongoing Webcast today at 8:00 a.m.

  $RGNX
• Tripadvisor Announces Management Departures and Transition Plan

  

  PR07:05:00·22m·TechnologyHigh short interest

  Tripadvisor Announces Management Departures and Transition Plan

  Tripadvisor, Inc. (NASDAQ:TRIP) today announced that the Board of Directors and Matt Goldberg have agreed that Mr. Goldberg will depart as President and Chief Executive Officer and as a member of the Board of Directors. The Board and Mr. Goldberg have agreed to the terms of his departure, pursuant to which Mr. Goldberg will remain in the role of CEO through February 16, 2027 to help ensure an orderly transition. Separately, Michael Noonan announced his intention to resign as Chief Financial Officer of the Company in order to pursue another opportunity. Mr. Noonan will continue in his role through December 31, 2026. Kristen Dalton will step in as i

  $TRIP
• Aurora Cannabis Announces Fiscal 2027 Second Quarter Results

  

  PR07:05:00·22m·Health Care

  Aurora Cannabis Announces Fiscal 2027 Second Quarter Results

  Delivers Net Revenue of $86.0 Million, Including Record International Medical Cannabis Net Revenue of $61.4 Million, Representing a 44% Yoy Increase Generated Adjusted EBITDA1 of $14.0 Million, With Free Cash Flow1 Outflow Improving by $22.4 Million Maintains Strong Balance Sheet With $133.0 Million of Cash, Cash Equivalents2 and Short-Term Investments With No Debt Aurora Cannabis Inc. (the "Company" or "Aurora") ((NASDAQ, TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter 2027 ending September 30, 2026. Aurora has cancelled its investor call, originally scheduled for November 12, 2026, a

  $ACB
• Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance

  

  PR07:05:00·22m·Health CarePenny stockHigh short interest

  Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance

  – Raises full-year 2026 LINZESS® (linaclotide) U.S. net sales guidance to $1.20 - $1.25 billion, representing greater than 35% increase year-over-year; Raises total 2026 revenue guidance to $485 - $510 million and adjusted EBITDA guidance to greater than $350 million – – Q3 2026 LINZESS U.S. net sales of $325 million; $880 million year-to-date U.S. net sales exceeds full-year 2025 U.S. net sales – – Total revenue of $133 million, GAAP net income of $60 million and record adjusted EBITDA of $98 million in Q3 2026 – – STARS-2 confirmatory Phase 3 trial of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) is ongoing; Planned U.S. and global site expansion on track –

  $IRWD
• Appian Announces Third Quarter 2026 Financial Results

  

  PR07:05:00·22m·Technology

  Appian Announces Third Quarter 2026 Financial Results

  Appian (NASDAQ:APPN) today announced financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights: Revenue: Cloud subscriptions revenue was $136.4 million, up 20% compared to the third quarter of 2025. Total subscriptions revenue increased 28% year-over-year to $187.8 million. Professional services revenue was $46.9 million, an increase of 18% compared to the third quarter of 2025. Total revenue was $234.6 million, up 25% compared to the third quarter of 2025. Cloud net annualized recurring revenue ("ARR") expansion was 120% as of September 30, 2026. Operating income and non-GAAP operating income:

  $APPN
• Vistance Networks Announces CEO Succession Plan

  

  PR07:05:00·22m·Technology

  Vistance Networks Announces CEO Succession Plan

  Chuck Treadway to Step Down Following Significant Strategic Transformation Board Initiates Search to Identify the Company’s Next CEO Vistance Networks, Inc. (NASDAQ:VISN) ("Vistance" or the "Company"), a global provider of intelligent network solutions, today announced that Chuck Treadway will step down as President and Chief Executive Officer ("CEO") of the Company and as a member of the Vistance Board of Directors on February 1, 2027. The Board of Directors has launched a comprehensive search for the Company’s next CEO and has retained a leading executive search firm to assist with the process. Mr. Treadway has served as President and CEO since October 2020. During his tenure, he ov

  $VISN
• Versigent CFO to Participate in RBC Capital Markets Global Industrials Conference on November 17

  

  PR07:05:00·22m·Consumer Discretionary

  Versigent CFO to Participate in RBC Capital Markets Global Industrials Conference on November 17

  Versigent PLC (NYSE:VGNT), a global leader in the design and manufacture of low- and high-voltage electrical architectures, today announced Chief Financial Officer, Doug Ostermann, will participate in a fireside chat at the RBC Capital Markets Global Industrials Conference on Tuesday, November 17, 2026 at 10:40 a.m. ET. The live webcast will be available at the following link: https://kvgo.com/2026-global-Industrials-conference/versigent-plc-november A replay of the webcast will be available at the same link and under the Events and Presentations section of Versigent's Investor Relations website at ir.versigent.com approximately 12 hours after the completion of the event and for the thr

  $VGNT
• Envoy Medical Reports Third Quarter 2026 Results and Highlights Continued Progress

  

  PR07:00:00·27m·Health CareLow floatHigh short interest

  Envoy Medical Reports Third Quarter 2026 Results and Highlights Continued Progress

  Company Reaches Six-Month Milestone in Pivotal Trial of Fully Implanted Cochlear ImplantSecond Module of Modular PMA Application Submitted to FDA Following Quarter EndWhite Bear Lake, Minnesota--(Newsfile Corp. - November 5, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today reported financial results for the third quarter ended September 30, 2026, and provided a business update, highlighting continued execution on its corporate initiatives."We continued to make significant progress with our investigational fully implanted cochlear implant during the third quarter, as

  $COCH
• Obsidian Energy Announces Third Quarter 2026 Results

  

  PR07:00:00·27m·Energy

  Obsidian Energy Announces Third Quarter 2026 Results

  Calgary, Alberta--(Newsfile Corp. - November 5, 2026) - OBSIDIAN ENERGY LTD. (TSX:OBE) (NYSE:OBE) ("Obsidian Energy", the "Company", "we", "us" or "our") is pleased to report our operating and financial results for the third quarter of 2026 (all amounts are in Canadian dollars unless otherwise noted). Highlights: Average production of 28,113 boe/d in the third quarter, generated strong funds flow from operations of $86.7 million with adjusted funds flow from operations of $80.7 million, excluding a $6.0 million share-based compensation recoveryRecent Belly River acquisition outperforming expectations with current production of ~2,600 boe/dExceptional Belly River results with 01-05 two-well p

  $OBE
• First Majestic Announces Q3 2026 Financial Results and Quarterly Dividend Payment

  

  PR07:00:00·27m·Basic Materials

  First Majestic Announces Q3 2026 Financial Results and Quarterly Dividend Payment

  Vancouver, British Columbia--(Newsfile Corp. - November 5, 2026) - First Majestic Silver Corp. (NYSE:AG) (TSX:AG) (FSE: FMV) (the "Company" or "First Majestic") is pleased to announce the Company's unaudited condensed interim consolidated financial results for the third quarter ended September 30, 2026. The full version of the quarterly financial statements and the accompanying management's discussion and analysis can be viewed on the Company's website at www.firstmajestic.com or under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov/edgar. All amounts in this news release are in U.S. dollars unless stated otherwise. First Majestic's third quarter revenues incr

  $AG
• Elauwit Connection Named Emerging Company to Watch at Inaugural Maravedis MDU Connectivity Awards

  

  PR07:00:00·27m·Consumer DiscretionaryPenny stock

  Elauwit Connection Named Emerging Company to Watch at Inaugural Maravedis MDU Connectivity Awards

  Expands on 2026 award recognitions as independent panel of property owners, REITs, analysts, and trade media recognizes Elauwit's Network-as-a-Service model, human-answered resident support, and growth as a public companyColumbia, South Carolina--(Newsfile Corp. - November 5, 2026) - Elauwit Connection, Inc. (NASDAQ:ELWT) ("Elauwit" or the "Company"), a national managed services provider of turnkey broadband and property-wide WiFi networks serving multifamily, student housing, and senior living communities, today announced it has been named Emerging Company to Watch at the inaugural Maravedis MDU Connectivity Awards 2026, presented by Calix. The Maravedis MDU Connectivity Awards, launched th

  $ELWT